Emerging Therapies for CNS Tumours: Key Clinical Trial Updates to Watch at ASCO 2026

Why It Matters

The emerging immunotherapy, targeted‑small‑molecule, and gene‑editing advances could expand the limited treatment arsenal for glioblastoma and other CNS tumors, potentially extending survival and ushering in precision‑medicine paradigms for a historically refractory disease.

Key Takeaways

• Extending temozolomide or carmustine wafers did not improve GBM survival
• NeoVax plus pembrolizumab raised median OS to 36.9 months in MGMT‑methylated GBM
• Bivalent EGFR/IL13Rα2 CAR‑T cells achieved 12‑month median OS in recurrent GBM
• Vorasidenib showed 44.1‑month median PFS in grade‑2 IDH‑mutant gliomas
• AAV6 NeuroD1 gene therapy reprogrammed glioma cells, 54.5% disease‑control rate

Pulse Analysis

Glioblastoma and other central nervous system (CNS) tumors remain among the deadliest cancers, with median survival often measured in months. At the 2026 American Society of Clinical Oncology (ASCO) meeting, two pivotal phase III studies—MAGMA and JCOG1703—confirmed that intensifying temozolomide cycles, adding neoadjuvant temozolomide, or implanting carmustine wafers does not extend overall or progression‑free survival beyond the current standard of care. These negative results underscore the urgent need for novel mechanisms that can overcome the blood‑brain barrier and the intrinsic heterogeneity of GBM.

Among the most promising signals were immunologic approaches. A phase I trial combined the personalized neoantigen vaccine NeoVax with pembrolizumab, delivering a median overall survival of 36.9 months in MGMT‑methylated patients—substantially higher than matched historical controls. Likewise, a bivalent CAR‑T cell product targeting EGFR and IL13Rα2 achieved a 12‑month median overall survival in recurrent GBM without long‑term toxicities, and even produced a durable 33‑month responder. These data suggest that both vaccine‑driven T‑cell priming and engineered cell therapies can “warm” the traditionally cold GBM microenvironment.

Targeted small‑molecule and gene‑editing strategies also entered the spotlight. Vorasidenib, a dual mIDH1/2 inhibitor, reported a 44.1‑month median progression‑free survival in grade‑2 IDH‑mutant gliomas, positioning it as a potential new standard for this molecular subset. In parallel, the first‑in‑human AAV6 NeuroD1 trans‑differentiation therapy reprogrammed malignant glioma cells into neuron‑like, non‑proliferative phenotypes, achieving a 54.5% disease‑control rate. While delivery across the blood‑brain barrier remains a hurdle, advances in implantable devices and convection‑enhanced infusion are expanding the therapeutic window, hinting at a future where multimodal, precision‑based regimens could finally shift the survival curve for CNS tumor patients.